Novartis has posted positive late-stage results for people with advanced liver cancer this week, while Amgen’s trial on a form of non-small cell lung cancer (NSCLC) caused by a genetic mutation also produced hopeful outcomes. So did a Novartis trial focused on a painful skin condition.
Source: Drug Industry Daily